Dr Geoffrey Liu talks to ecancer about a poster he co-authored at ESMO 2025.

The TRUST-II global phase II study evaluated taletrectinib, a next-generation CNS-active ROS1 inhibitor, in patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) who had previously been treated with entrectinib.

Among 10 entrectinib-pretreated patients, taletrectinib achieved a systemic objective response rate (ORR) of 80% and an intracranial ORR of 50%, showing strong activity even after prior ROS1 TKI therapy. Some patients maintained clinical benefit beyond radiographic progression.

The safety profile was consistent with prior findings; most common adverse events were elevated liver enzymes and gastrointestinal symptoms, generally manageable with dose adjustments. No treatment-related discontinuations or deaths occurred.

Dr Liu summarises that taletrectinib demonstrated promising efficacy and tolerability as a second-line treatment for entrectinib-pretreated ROS1+ NSCLC, supporting its potential role in managing this patient population.